Clinical Trial Update: BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of BIBW 2992 (afatinib) in combination with letrozole for hormonoresistant metastatic breast cancer has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BIBW 2992 (afatinib)
• Letrozole (letrozole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-19